Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Director | June 05, 2018 | June 07, 2018 |
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 05, 2026 | June 10, 2026 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 17, 2026 | June 22, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Chief Admin Officer & SVP | February 21, 2020 | February 25, 2020 |
| NEOGENOMICS INCNEO · Entity 2096 | Chief Legal Officer | March 01, 2022 | March 04, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2028-06-05 | Direct | 15,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Arcutis Biotherapeutics, Inc.
Report date June 05, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,901 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 5,778 · Balance 27,901 F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.23 · Expires 2036-06-05 | Direct | 16,667 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 16,667 · Balance 16,667 F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
F2: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.
CytomX Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2036-06-16 | Direct | 59,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 59,000 · Balance 59,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
IRONWOOD PHARMACEUTICALS INC
Report date February 21, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 265,991 |
Ending reported balance
After 2020-02-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-02-21 · Sale · Disposed 2,753 · Balance 278,566 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 2 · 2020-02-21 · Sale · Disposed 3,410 · Balance 275,156 F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2020-02-21 · Sale · Disposed 2,984 · Balance 272,172 F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 4 · 2020-02-21 · Sale · Disposed 6,181 · Balance 265,991 F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
F4: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
F5: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,396 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 42,036 · Balance 147,396 F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 102,623 |
Reported balance
After 2022-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-01 · Grant · Acquired 102,623 · Balance 102,623 F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.21 · Expires 2028-08-17 | Direct | 63,331 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 63,331 F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3.
F3: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 12,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 24, 2020
Section 16 reporting ended · disclosed 2020-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2029-11-10 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 20:48 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 59,000 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0001610717-26-000276 · form4.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001601360-26-000002 · wk-form4_1781641080.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001601360-26-000002 · wk-form4_1781641080.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,481 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042040 · wk-form4_1781054453.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:20 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042040 · wk-form4_1781054453.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,901 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001601360-25-000007 · wk-form4_1763767283.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 16,532 | $27.55 | $455,441.72 |
DisclosureSEC source: 0001601360-25-000007 · wk-form4_1763767283.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,123 F2 · kind: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $27.32 to $27.72, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 12,220 | $7.51 | $91,772.20 |
DisclosureSEC source: 0001601360-25-000007 · wk-form4_1763767283.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001601360-25-000003 · wk-form4_1750111834.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F4 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001601360-25-000003 · wk-form4_1750111834.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,216 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000023 · wk-form4_1750119419.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:17 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000023 · wk-form4_1750119419.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,435 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 15, 2024, maintained by the Company. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:16 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001610717-25-000210 · form4.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000100 · wk-form4_1718743886.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000100 · wk-form4_1718743886.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,826 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000013 · wk-form4_1718050236.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000013 · wk-form4_1718050236.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,175 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,200 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-24-015590 · form4-06052024_080637.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,374 Underlying: Common Stock · 18,200 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option is fully vested and exercisable. F3 · balance_after: Reporting Person has transferred 30,374 vested stock options to Reporting Person's ex-spouse pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Accordingly, Reporting Person will not report beneficial ownership of or dispositions or acquisitions of the underlying shares in future Section 16(a) filings. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 18,200 | $73.00 | $1,328,600.00 |
DisclosureSEC source: 0001415889-24-015590 · form4-06052024_080637.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,625 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 1, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 20:59 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 18,200 | $5.35 | $97,370.00 |
DisclosureSEC source: 0001415889-24-015590 · form4-06052024_080637.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:32 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000243 · form4.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001610717-23-000179 · form4.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037501 · doc4.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037501 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001787306-23-000056 · wk-form4_1685747268.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:08 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000056 · wk-form4_1685747268.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,687 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:06 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013072 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-22-034050 · doc4.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:29 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034050 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 11,796 | $0.00 Strike: $20.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012319 · doc1.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:56 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012319 · doc1.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,312 F1 · balance_after: Includes 4,312 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 102,623 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001077183-22-000044 · wf-form4_164635555368681.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,623 Underlying: Common Stock · 102,623 shares Expires 2029-03-01 F4 · derivative.exercise_date: On March 1, 2022, Ms. Gilbert was granted 102,623 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 42,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000044 · wf-form4_164635555368681.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,396 F1 · shares: On March 1, 2022, Ms. Gilbert was granted 42,036 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2 · balance_after: This balance includes 97 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| December 31, 2021 Filed Feb 9, 2022 00:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherCommon Stock | 177 | $31.30 | $5,540.10 |
DisclosureSEC source: 0001077183-22-000009 · wf-form5_164436554542544.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,263 F1 · kind: These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2021. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:02 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 45,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000272 · wf-form4_164090535269636.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,086 F1 · kind: On December 30, 2021, Ms. Gilbert was granted 45,858 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock · Derivative | 63,331 | $0.00 Strike: $42.21 | $0.00 |
DisclosureSEC source: 0001077183-21-000214 · wf-form4_162940935536512.xml · derivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,331 Underlying: Common Stock · 63,331 shares Expires 2028-08-17 F1 · derivative.exercise_date: On August 17, 2021, Ms. Gilbert was granted 63,331 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:42 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 59,228 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000214 · wf-form4_162940935536512.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,228 Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 22:43 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012364 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:36 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 13,391 | $0.00 Strike: $27.77 | $0.00 |
DisclosureSEC source: 0001567619-21-012027 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 22:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $21.49 | $0.00 |
DisclosureSEC source: 0001209191-21-037898 · doc4.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 21:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012299 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 01, 2020 Filed May 2, 2020 00:09 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 37,500 | $0.00 Strike: $26.00 | $0.00 |
DisclosureSEC source: 0001567619-20-008827 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-05-01 F1 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of May 1, 2021, May 1, 2022 and May 1, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 22:49 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.25 | $0.00 |
DisclosureSEC source: 0001567619-20-008617 · doc1.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-04-26 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from April 27, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 6,181 | $11.63 | $71,885.03 |
DisclosureSEC source: 0001209191-20-012479 · doc4.xml · nonDerivative · entry 4 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,991 F5 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,984 | $11.63 | $34,703.92 |
DisclosureSEC source: 0001209191-20-012479 · doc4.xml · nonDerivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,172 F4 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,410 | $11.63 | $39,658.30 |
DisclosureSEC source: 0001209191-20-012479 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,156 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:33 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,753 | $11.63 | $32,017.39 |
DisclosureSEC source: 0001209191-20-012479 · doc4.xml · nonDerivative · entry 1 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,566 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:32 UTC | Dermira, Inc. DERM · Entity 11896 | Disposition to issuerDirector Stock Options (Right to buy) · Derivative | 20,000 | Not disclosed Strike: $8.05 | Not disclosed |
DisclosureSEC source: 0001562180-20-001619 · primarydocument.xml · derivative · entry 1 Gilbert Halley E · CIK 0001601360 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-11-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $10.02 | $0.00 |
DisclosureSEC source: 0001209191-20-006267 · doc4.xml · derivative · entry 3 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 60,000 shares Expires 2020-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, granted as an annual performance award, is presently exercisable in full. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 60,000 | $12.05 | $723,000.00 |
DisclosureSEC source: 0001209191-20-006267 · doc4.xml · nonDerivative · entry 2 Gilbert Halley E · CIK 0001601360 · Chief Admin Officer & SVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,319 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.21, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.